Alexander Dydyk, DO
Pain Medicine · Avondale, AZNPI 1912435694
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.2%), travel and lodging and entertainment — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Medtronic at 48.0% of the total.
Across 310 payments — averaging $67.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$10K
- Abbott$3K
- Boston Scientific$3K
- Spinal Simplicity, LLC$1K
- Nalu Medical, Inc.$502
- Foundation Fusion Solutions, LLC$385
- plus $3K from 31 others
What the payments were for
- Travel & lodging$8,72742%
- Food & beverage$12,16958%
- Entertainment$260%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 120 | $10,045 |
| Abbott | 34 | $3,387 |
| Boston Scientific | 29 | $2,565 |
| Spinal Simplicity, LLC | 13 | $1,344 |
| Nalu Medical, Inc. | 10 | $502 |
| Foundation Fusion Solutions, LLC | 18 | $385 |
| SPR Therapeutics, Inc | 5 | $339 |
| Novo Nordisk | 17 | $317 |
| Nevro Corp. | 8 | $295 |
| Angiodynamics, Inc. | 2 | $197 |
| Vertos Medical, Inc. | 2 | $172 |
| Lilly USA, LLC | 3 | $139 |
| Amgen | 6 | $113 |
| AbbVie(2 entities) | 4 | $97 |
| Protega Pharmaceutials Inc | 2 | $96 |
| Averitas Pharma Inc. | 3 | $92 |
| Sonex Health, Inc. | 2 | $86 |
| Stryker | 2 | $85 |
| Relievant Medsystems, Inc. | 1 | $79 |
| Bioventus LLC | 4 | $75 |
| Avanos Medical | 3 | $67 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $49 |
| Collegium Pharmaceutical, Inc. | 3 | $48 |
| Stimwave Technologies Incorporated | 1 | $45 |
| Currax Pharmaceuticals LLC | 3 | $44 |
| Painteq LLC | 2 | $43 |
| Pacira Pharmaceuticals Incorporated | 1 | $27 |
| DJO, LLC | 1 | $26 |
| Tenex Health Inc. | 1 | $25 |
| Bayer | 1 | $20 |
| Biotronik NRO, Inc. | 1 | $19 |
| Vericel Corporation | 1 | $19 |
| Baxter Healthcare | 1 | $18 |
| Impulse Dynamics (USA) Inc. | 1 | $17 |
| Vertex | 1 | $17 |
| Impactortho, Inc. | 1 | $15 |
| Cook Medical LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$2,481
- INTELLIS ADAPTIVESTIM$2,035
- VANTA ADAPTIVESTIM$1,656
- Superion Indirect Decompression System$1,260
- HA MINUTEMAN G3-R$1,195
- SYNCHROMEDII$914
- INTELLIS$671
- INCEPTIV$618
- LIBERTY SI$521
- Proclaim IPG$263
- ICEfx Cryoablation System$243
- KYPHON EXPRESS II KYPHOPAK TRAY$229
- ETERNA$159
- mild Device Kit$141
- Senza$132
- Cryoablation needles$127
- GENERAL PAIN MANAGEMENT$124
- ENTRADA$119
- Wegovy$119
- Avista MRI$113
How this compares
$20,922 in reported general payments places this provider in the 85th percentile of 180 pain medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 22 | $22,023 |
| OzempicSemaglutide | 21 | $20,728 |
| Xtampza ErOxycodone Myristate | 14 | $8,642 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 157 | $6,015 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 154 | $4,620 |
| Duloxetine Hcl | 240 | $4,025 |
| Buprenorphine | 26 | $3,263 |
| Gabapentin | 189 | $3,208 |
| Fentanyl | 22 | $2,775 |
| Oxycodone Hcl | 177 | $2,686 |
| Pregabalin | 66 | $1,787 |
| Lidocaine | 25 | $1,727 |
| Testosterone Cypionate | 22 | $1,522 |
| Diclofenac Sodium | 33 | $1,252 |
| Morphine Sulfate ErMorphine Sulfate | 39 | $866 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $139 | $22,02322 claims |
| Novo NordiskOzempic | $317 | $20,72821 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $48 | $8,64214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 180 pain medicine providers in Arizona.
Other pain medicine in Avondale
- Eric CornidezTucson$496K
- Tory McJunkinScottsdale$204K
- Minesh ZaveriPhoenix$187K
- Chad PletnickOro Valley$137K
- Tristan PicoChandler$121K
- Selaiman NooriLake Havasu City$104K
- Christine HaddadPhoenix$98K
- Samir PatelOro Valley$70K
- Vivek IyerScottsdale$70K
- Kirk BowdenMesa$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.